# Anbio Biotechnology (NNNN)

- Sector: Healthcare · Industry: Medical Instruments and Supplies
- SEC CIK: 0001982708 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001982708))
- Full page: https://inspectstocks.com/stocks/nnnn
- Data as of: price 2026-09-28; newest filing used 2026-04-07; latest fiscal period ended 2025-12-31

## Grade

**B+** on the balance-sheet rubric used for lenders, 3 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | $6.4M |  |
| Earnings growing overall | failed | $6.4M | $10M |
| Earnings growing recently | passed | $6.4M | $2.4M |
| Earns well on its assets | passed | 21.2% |  |
| Book value per share growing | not answerable | $0.69 |  |

Business quality (the + / − mark): 4 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 74.1% |  |
| Healthy profit margin | passed | 74.1% |  |
| Strong operating margin | passed | 66.7% |  |
| Good return on equity | passed | 21.2% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $8.6M |
| Net income, trailing twelve months | $6.4M |
| Net margin | 74.1% |
| Operating margin | 66.7% |
| Return on equity | 21.2% |
| Diluted EPS, trailing twelve months | $0.15 |
| Share price | $6.03 |
| Market value | $263.3M |
| Price / earnings | 41.0x |
| Price / sales | 30.5x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/nnnn)
- [Financial statements](https://inspectstocks.com/stocks/nnnn/financials)
- [Competitors](https://inspectstocks.com/stocks/nnnn/peers)
- [Earnings](https://inspectstocks.com/stocks/nnnn/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.